Goldman Sachs raised the firm’s price target on iRhythm (IRTC) to $211 from $202 and keeps a Neutral rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- Evercore ISI upgrades four, downgrades six in MedTech and Tools
- iRhythm upgraded to Outperform from In Line at Evercore ISI
- iRhythm price target lowered to $215 from $230 at Truist
- iRhythm price target lowered to $220 from $235 at Baird
- iRhythm price target raised to $205 from $195 at Morgan Stanley